DXR

Conviction 26HealthcareScan · Mon, Aug 10, 2026

DXR$10.11+0.00%

ResistanceSupportVol 14Insider buy

Vol MA14 1.47K

May 8May 27Jun 15Jul 2Jul 22Aug 7

DAXOR CORPSURGICAL & MEDICAL INSTRUMENTS & APPARATUSwww.daxor.com ↗

Price10.11

Change+0.00%

Gap—

Rel volume0.49×

Avg volume1.59K

Avg $ vol16.54K

SMA 208.96

SMA 509.48

SMA 20010.73

Price vs 50+6.67%

Price vs 200-5.78%

MA stackmixed

50/200 cross—

Supertrenddown · 10.70

RSI (14)51

MACD hist-0.18

MACD crossbear · 1d

Stoch %K / %D91 / 59

ADX (14)11

+DI / −DI50 / 46

RSI divergence—

MACD divergence—

ATR %+35.95%

ADR %3.65%

52w high14.75

52w low0.0000

From 52w high-31.46%

Above 52w low—

New 52w highNo

SqueezeOff

Bollinger width168.30%

%B0.58

Donchian pos84.46%

Donchian high11.97

Donchian low0.0000

AVWAP (52w high)11.05

vs AVWAP high-8.51%

AVWAP (52w low)11.19

vs AVWAP low-9.68%

OBV trendDown

Chaikin MF (20)-0.38

Today vs 20d0.49×

Avg vol (14d)1.47K

Avg vol (20d)1.59K

Avg $ vol (20d)16.54K

Market cap42.42M

RS 3m (vs SPY)-1.04%

RS 6m (vs SPY)-31.65%

RS line new highNo

Trend template1/8

Technical rank29.8

1 week-3.71%

1 month+0.00%

3 months+4.66%

6 months-17.54%

1 year+1.10%

YTD-29.60%

P/E-5.90

P/B1.17

P/S29.33

P/FCF-6.40

EPS-1.70

Div yield2.49%

ROE-19.84%

ROA-8.38%

Debt/Eq—

Current1.66

EV/EBITDA—

Gross margin54.89%

Net margin-496.81%

Rev growth-8.42%

EPS growth-244.63%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value42.36M

Revenue340.91K

Net income-4.18M

Gross profit191.53K

Free cash flow-6.63M

IndustrySURGICAL & MEDICAL INSTRUMENTS & APPARATUS

ExchangeNasdaq

Shares out5.84M

Employees750

ListedMon, Jul 25, 1983

Free float2.04M

Float %40.5%

Short interest1.47K

Days to cover1.0d

Short volume89.7%

Squeeze score25 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction26 / 100

Pattern quality—

Tech rank29.8 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance11.56

Support0.0000

Days since event—

Candle confirm—

News sentiment—

Financials as of Fri, Sep 30, 2011 · quarterly.

Congress activity

Disclosed STOCK Act trades in DXR

All disclosures →

No recent disclosed trades by Congress in DXR. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in DXR · 8 buys

Insider	Side	Shares	Value	Traded	Filed
DesRosiers Caleb Director · Stock options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
Feuer Edward Director · Stock Options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
Goudie Joy S. Director · Stock Options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
Feldschuh Jonathan Adam Chief Scientific Officer · Daxor Common Stock · 2026-06-23	Grant	25K	—	2026-06-23	2026-06-25
Cremisi Henry D. Director · Stock Options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
Feldschuh Michael Richard Chief Executive Officer · Daxor Common Stock · 2026-06-23	Grant	30K	—	2026-06-23	2026-06-25
Michel Robert J Chief Financial Officer · Daxor Common Stock · 2026-06-23	Grant	12K	—	2026-06-23	2026-06-25
Feldschuh Michael Richard Chief Executive Officer · Daxor Common Stock · 2026-04-08	Buy	1K	$9K	2026-04-08	2026-04-10

SEC filings

EDGAR filings in DXR · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.